Aytu BioPharma (NASDAQ:AYTU – Get Free Report) and Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.
Risk and Volatility
Aytu BioPharma has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.
Insider and Institutional Ownership
33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 4.9% of Aytu BioPharma shares are held by company insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aytu BioPharma | $66.38 million | 0.36 | -$13.56 million | ($4.58) | -0.49 |
| Milestone Pharmaceuticals | $1.55 million | 73.98 | -$63.06 million | ($0.69) | -1.33 |
Aytu BioPharma has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current recommendations for Aytu BioPharma and Milestone Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aytu BioPharma | 1 | 1 | 3 | 0 | 2.40 |
| Milestone Pharmaceuticals | 1 | 1 | 4 | 1 | 2.71 |
Aytu BioPharma currently has a consensus price target of $10.75, indicating a potential upside of 382.06%. Milestone Pharmaceuticals has a consensus price target of $6.40, indicating a potential upside of 594.90%. Given Milestone Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Aytu BioPharma.
Profitability
This table compares Aytu BioPharma and Milestone Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aytu BioPharma | -60.17% | -69.93% | -13.25% |
| Milestone Pharmaceuticals | N/A | -288.33% | -58.27% |
Summary
Milestone Pharmaceuticals beats Aytu BioPharma on 10 of the 15 factors compared between the two stocks.
About Aytu BioPharma
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
